CTC Alternative Strategies’s Pfizer PFE Stock Holding History

CTC Alternative Strategies’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-21,080	Closed	-$13.9M	–	169
2013 Q2	$13.9M	Buy	+21,080	New	+$582K	3.75%	5

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

CTC Alternative Strategies's PFE Position: Q2 2025 in Review

CTC Alternative Strategies sold out of Pfizer (PFE) in Q2 2025, closing a stake of 219,860 shares — an estimated $5.57M sold.

CTC Alternative Strategies first reported a position in PFE in Q2 2013 and held it in 5 quarters. The position peaked at $56.1M in Q2 2013. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

CTC Alternative Strategies reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
CTC Alternative Strategies sold 219,860 Pfizer shares in Q2 2025, an estimated $5.57M.
CTC Alternative Strategies first reported a position in Pfizer in Q2 2013 and held it in 5 quarters.
CTC Alternative Strategies's Pfizer position peaked at $56.1M in Q2 2013.
2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on CTC Alternative Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.